363 related articles for article (PubMed ID: 17283142)
41. [Mechanism of resistance to growth inhibition by transforming growth factor-beta 1 (TGF-beta 1) in primary lung cancer and new molecular targets in therapy].
Gemma A; Uematsu K; Hagiwara K; Takenoshita S; Kudoh S
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1253-9. PubMed ID: 10945024
[TBL] [Abstract][Full Text] [Related]
42. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
[TBL] [Abstract][Full Text] [Related]
43. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
44. Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Zhou R; Xiong B; Song H; Liu S; Wang X
Oncol Rep; 2008 Dec; 20(6):1449-56. PubMed ID: 19020727
[TBL] [Abstract][Full Text] [Related]
45. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
[TBL] [Abstract][Full Text] [Related]
46. Down-regulation of transforming growth factor beta receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity.
Bae HJ; Eun JW; Noh JH; Kim JK; Jung KH; Xie HJ; Park WS; Lee JY; Nam SW
Oncol Rep; 2009 Sep; 22(3):475-80. PubMed ID: 19639191
[TBL] [Abstract][Full Text] [Related]
47. Monomeric type I and type III transforming growth factor-β receptors and their dimerization revealed by single-molecule imaging.
Zhang W; Yuan J; Yang Y; Xu L; Wang Q; Zuo W; Fang X; Chen YG
Cell Res; 2010 Nov; 20(11):1216-23. PubMed ID: 20625381
[TBL] [Abstract][Full Text] [Related]
48. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
[TBL] [Abstract][Full Text] [Related]
49. Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Moodley R; Snyman C; Odhav B; Bhoola KD
Biol Chem; 2005 Apr; 386(4):375-82. PubMed ID: 15899700
[TBL] [Abstract][Full Text] [Related]
50. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
51. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
52. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo.
Shukeir N; Pakneshan P; Chen G; Szyf M; Rabbani SA
Cancer Res; 2006 Sep; 66(18):9202-10. PubMed ID: 16982764
[TBL] [Abstract][Full Text] [Related]
53. PC-1/PrLZ contributes to malignant progression in prostate cancer.
Zhang H; Wang J; Pang B; Liang RX; Li S; Huang PT; Wang R; Chung LW; Zhau HE; Huang C; Zhou JG
Cancer Res; 2007 Sep; 67(18):8906-13. PubMed ID: 17875733
[TBL] [Abstract][Full Text] [Related]
54. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.
Kim IY; Ahn HJ; Lang S; Oefelein MG; Oyasu R; Kozlowski JM; Lee C
Clin Cancer Res; 1998 Jul; 4(7):1625-30. PubMed ID: 9676836
[TBL] [Abstract][Full Text] [Related]
55. A role for the WWOX gene in prostate cancer.
Qin HR; Iliopoulos D; Semba S; Fabbri M; Druck T; Volinia S; Croce CM; Morrison CD; Klein RD; Huebner K
Cancer Res; 2006 Jul; 66(13):6477-81. PubMed ID: 16818616
[TBL] [Abstract][Full Text] [Related]
56. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.
Wu GJ; Peng Q; Fu P; Wang SW; Chiang CF; Dillehay DL; Wu MW
Gene; 2004 Mar; 327(2):201-13. PubMed ID: 14980717
[TBL] [Abstract][Full Text] [Related]
57. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
58. The type III TGF-beta receptor suppresses breast cancer progression.
Dong M; How T; Kirkbride KC; Gordon KJ; Lee JD; Hempel N; Kelly P; Moeller BJ; Marks JR; Blobe GC
J Clin Invest; 2007 Jan; 117(1):206-17. PubMed ID: 17160136
[TBL] [Abstract][Full Text] [Related]
59. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
Criswell TL; Dumont N; Barnett JV; Arteaga CL
Cancer Res; 2008 Sep; 68(18):7304-12. PubMed ID: 18794117
[TBL] [Abstract][Full Text] [Related]
60. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
Yoo YA; Kang MH; Kim JS; Oh SC
Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
